{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-24-000137","form_type":"8-K","ticker":"TEVA","cik":"0000818686","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","filed_at":"2024-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.998950+00:00","generated_at":"2026-06-06T14:22:15.132278+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Teva FY2023 revenue $15.8B, Non-GAAP EPS $2.56; AUSTEDO $1.2B; 2024 guidance issued; revises prior results","bullets":["Full-year 2023 revenues $15,846M, up 7% in local currency; Q4 revenues $4,465M.","Non-GAAP diluted EPS $2.56 (vs $2.52 in 2022); GAAP net loss $(0.50) per share.","AUSTEDO annual revenue exceeded $1.2B (+28%); AJOVY $435M (+16%).","2024 outlook: revenue $15.7-$16.3B, Non-GAAP EPS $2.20-$2.50, free cash flow $1.7-$2.0B.","Revision: $132M contingent consideration understatement; material weakness in internal controls identified."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-24-000137","json":"https://secwatch.observer/filing/0001157523-24-000137.json","markdown":"https://secwatch.observer/filing/0001157523-24-000137.md","text":"https://secwatch.observer/filing/0001157523-24-000137.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818686/000115752324000137/0001157523-24-000137-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818686/000115752324000137/a53889897.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T14:22:15.132278+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"211ef120834eb3e480e2d8f25f71bdcf7b76cb89","claim":"TEVA PHARMACEUTICAL INDUSTRIES LTD reported 2024 results: revenue $15.7 - $16.3 billion, EPS $2.20 - $2.50. Guidance initiated.","evidence_excerpt":"2024 Business Outlook : Revenues of $15.7 - $16.3 billion Non-GAAP operating income of $4.0-$4.5 billion Adjusted EBITDA of $4.5 - $5.0 billion Non-GAAP diluted EPS of $2.20 - $2.50 Free cash flow of $1.7 - $2.0 billion","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/818686/000115752324000137/0001157523-24-000137-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2024"},{"label":"Revenue","value":"$15.7 - $16.3 billion"},{"label":"EPS","value":"$2.20 - $2.50"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"4290b278ddb055bc22c543d297ee20353b21a426","claim":"TEVA PHARMACEUTICAL INDUSTRIES LTD reported the quarter ended December 31, 2023 results: revenue $4.5 billion, EPS $0.41. Guidance initiated.","evidence_excerpt":"Q4 2023 FY 2023 Revenues $4.5 billion $15.8 billion GAAP diluted earnings (loss) per share $0.41 $(0.50) Non-GAAP diluted EPS $1.00 $2.56","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/818686/000115752324000137/0001157523-24-000137-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2023"},{"label":"Revenue","value":"$4.5 billion"},{"label":"EPS","value":"$0.41"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"4aa59f668326028181ce6f355c14d3d53d5cd539","claim":"TEVA PHARMACEUTICAL INDUSTRIES LTD reported the fiscal year ended December 31, 2023 results: revenue $15.8 billion, EPS $(0.50). Guidance initiated.","evidence_excerpt":"Q4 2023 FY 2023 Revenues $4.5 billion $15.8 billion GAAP diluted earnings (loss) per share $0.41 $(0.50) Non-GAAP diluted EPS $1.00 $2.56","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/818686/000115752324000137/0001157523-24-000137-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Revenue","value":"$15.8 billion"},{"label":"EPS","value":"$(0.50)"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}